Keio University

Sumitomo Dainippon Pharma Co., Ltd.

Shigeto Shimmura

Satoru Yoshida

Hideyuki Okano

Kazuo Tsubota

Shin Hatou

Akiyoshi Kishino

Emi Inagaki

Miho Maeda

Masahiro Omoto

Using the medium of the present invention for inducing a cornea endothelial substitute cell from an iPS cell, the medium containing an insulin-like growth factor and a STAT3 activator, and not containing a basic fibroblast growth factor or a ROCK inhibitor, and the method of the present invention for inducing corneal endothelial substitute cells from iPS cells by using the medium, it becomes possible to efficiently produce corneal endothelial substitute cells, particularly to efficiently produce corneal endothelial substitute cells from iPS cells. Furthermore, it becomes possible to stably produce large amounts of corneal endothelial substitute cells by inducing differentiation of iPS cells into corneal endothelial substitute cells more efficiently.

Medium comprising serum replacement, IGF1, STAT3 activator and adrenal gland hormone without BFGF or rock inhibitor for producing corneal endothelial substitute cells from iPS cells and a method thereof

The present invention provides a method for evaluating tumorigenicity of a test cell, including transplanting the cell into anterior chamber of an eye of an experimental animal, and observing the presence or absence of tumor formation. According to the present invention, tumorigenicity can be evaluated in a short period and conveniently.

Rapid tumorigenicity screening system

The problem of the present invention is to provide a method of efficiently producing therapeutic alternative corneal endothelial cells, particularly, a method capable of stably producing them in a condition suitable for intraocular transplantation (in the anterior chamber) in a large amount. Furthermore, the present invention aims to provide a composition for transplantation, which is preferable for intraocular administration, particularly, into the anterior chamber. A therapeutic alternative corneal endothelial cell sphere can be produced by culturing stem cells in suspension in a differentiation induction medium containing a GSK3 inhibitor, retinoic acid and a ROCK inhibitor. Addition of a viscoelastic substance during intraocular (into the anterior chamber) transplantation of the sphere or cultured corneal endothelial cells dispersed into single cells can increase the number of adherent cells after transplantation.

Method for producing therapeutic corneal endothelial substitute cell sphere

The invention provides a method of efficiently producing corneal endothelial cells, particularly from corneal stroma or iPS cell-derived neural crest stem cells, a method of producing corneal endothelial cells stably in a large amount by inducing more efficient differentiation of stem cells into corneal endothelial cells, and a medicament containing corneal endothelial cells. The method of inducing differentiation of stem cells into corneal endothelial cells includes a step of culturing the stem cells in a differentiation induction medium containing a GSK3 inhibitor (preferably a GSK3&#x3b2; inhibitor) and retinoic acid, with the differentiation induction medium preferably further containing one or more of TGFb2, insulin, a ROCK inhibitor, and the like.

Growing community of inventors

Tokyo, Japan

Shigeto Shimmura